Cholesterol and Coronary Heart Disease

作者: Scott M. Grundy

DOI: 10.1001/ARCHINTE.1997.00440320055006

关键词:

摘要: Recent clinical trials have demonstrated that reductions of serum low-density lipoprotein (LDL) levels substantially decrease the risk for coronary heart disease. These confirm other lines evidence high LDL are a critical atherogenic factor. Aggressive lowering in high-risk patients promises to significantly reduce morbidity and mortality from disease first third 21st century. However, several additional measures will be required marginalize Other abnormalities factors, eg, cigarette smoking, hypertension, diabetes mellitus, must controlled obtain full benefit LDL-lowering therapy. Moreover, health care delivery system reorganized put more emphasis on prevention. Although much can achieved through application current knowledge prevention efforts, further advances new research remove as major cause death United States. Arch Intern Med. 1997;157:1177-1184

参考文章(56)
R Havel, McCollum Award Lecture, 1993: triglyceride-rich lipoproteins and atherosclerosis--new perspectives. The American Journal of Clinical Nutrition. ,vol. 59, pp. 795- 796 ,(1994) , 10.1093/AJCN/59.4.795
N.E. Miller, D.S. Thelle, O.H. Førde, O.D. Mjøs, The Tromso Heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. The Lancet. ,vol. 309, pp. 965- 968 ,(1977) , 10.1016/S0140-6736(77)92274-7
Daniel Steinberg, Lipoproteins and Atherogenesis JAMA. ,vol. 264, pp. 3047- 3052 ,(1990) , 10.1001/JAMA.1990.03450230083034
Margo A. Denke, Cholesterol-Lowering Diets Archives of Internal Medicine. ,vol. 155, pp. 17- 26 ,(1995) , 10.1001/ARCHINTE.1995.00430010021004
M. S. Guyer, F. S. Collins, How is the Human Genome Project doing, and what have we learned so far? Proceedings of the National Academy of Sciences of the United States of America. ,vol. 92, pp. 10841- 10848 ,(1995) , 10.1073/PNAS.92.24.10841
Paula K. Locker, Gail L. Jungbluth, Steven F. Francom, George S. Hughes, Lifibrol: A novel lipid‐lowering drug for the therapy of hypercholesterolemia Clinical Pharmacology & Therapeutics. ,vol. 57, pp. 73- 88 ,(1995) , 10.1016/0009-9236(95)90269-4
David A. Gordon, Haris Jamil, Richard E. Gregg, Sven-Olof Olofsson, Jan Borén, Inhibition of the Microsomal Triglyceride Transfer Protein Blocks the First Step of Apolipoprotein B Lipoprotein Assembly but Not the Addition of Bulk Core Lipids in the Second Step Journal of Biological Chemistry. ,vol. 271, pp. 33047- 33053 ,(1996) , 10.1074/JBC.271.51.33047